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Abstract The National Institute for Health and Care
Excellence (NICE) invited the company that manufactures
ramucirumab (Cyramza, Eli Lilly and Company) to sub-
mit evidence of the clinical and cost effectiveness of the
drug administered alone (monotherapy) or with paclitaxel
(combination therapy) for treating adults with advanced
gastric cancer or gastro-oesophageal junction (GC/GOJ)
adenocarcinoma that were previously treated with
chemotherapy, as part of the Institute’s single technology
appraisal (STA) process. Kleijnen Systematic Reviews Ltd
(KSR), in collaboration with Erasmus University Rotter-
dam, was commissioned to act as the Evidence Review
Group (ERG). This paper describes the company’s sub-
mission, the ERG review, and NICE’s subsequent deci-
sions. Clinical effectiveness evidence for ramucirumab
monotherapy (RAM), compared with best supportive care
(BSC), was based on data from the REGARD trial. Clinical
effectiveness evidence for ramucirumab combination
therapy (RAM ? PAC), compared with paclitaxel
monotherapy (PAC), was based on data from the
RAINBOW trial. In addition, the company undertook a
network meta-analysis (NMA) to compare RAM ? PAC
with BSC and docetaxel. Cost-effectiveness evidence of
monotherapy and combination therapy relied on partitioned
survival, cost-utility models. The base-case incremental
cost-effectiveness ratio (ICER) of the company was
£188,640 (vs BSC) per quality-adjusted life-year (QALY)
gained for monotherapy and £118,209 (vs BSC) per QALY
gained for combination therapy. The ERG assessment
indicated that the modelling structure represented the
course of the disease; however, a few errors were identified
and some of the input parameters were challenged. The
ERG provided a new base case, with ICERs (vs BSC) of
£188,100 (monotherapy) per QALY gained and £129,400
(combination therapy) per QALY gained and conducted
additional exploratory analyses. The NICE Appraisal
Committee (AC), considered the company’s decision
problem was in line with the NICE scope, with the
exception of the choice of comparators for the combination
therapy model. The most plausible ICER for ramucirumab
monotherapy compared with BSC was £188,100 per
QALY gained. The Committee considered that the ERG’s
exploratory analysis in which RAM ? PAC was compared
with PAC by using the direct head-to-head data (including
utilities) from the RAINBOW trial, provided the most
plausible ICER (i.e. £408,200 per QALY gained) for
ramucirumab combination therapy. The Committee con-
cluded that end-of-life considerations cannot be applied for
either case, since neither failed to offer an extension to life
of at least 3 months. The company did not submit a patient
access scheme (PAS). After consideration of the evidence,
the Committee concluded that ramucirumab alone or with
paclitaxel could not be considered a cost-effective use of
National Health Service resources for treating advanced
GC/GOJ patients that were previously treated with
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chemotherapy, and therefore its use could not be recom-
mended. We might wonder if a complete STA process is
necessary for treatments without a PAS, which are,
according to the company’s submission, already associated
with ICERs far above the currently accepted threshold in
all (base-case, sensitivity and scenario) analyses.
Key Points for Decision Makers
Ramucirumab (RAM) monotherapy and combination
therapy seem to be clinically effective for treating
advanced gastric cancer or gastro-oesophageal
junction adenocarcinoma patients who were
previously treated by chemotherapy, as both
treatments (monotherapy and combination therapy)
lead to limited increase in overall survival and
progression-free survival compared with best
supportive care (BSC) and paclitaxel alone,
respectively, from REGARD and RAINBOW trials.
The evidence review group (ERG) considered that
other comparators than BSC and docetaxel, which
were mentioned in the scoping document (e.g.
paclitaxel, irinotecan etc.) should also have been
included. Furthermore, the ERG mentioned that the
results of the indirect treatment comparison (ITC)
should be interpreted with caution, due to
considerable heterogeneity between the trials and the
exclusion of potentially relevant trials from the ITC
by the company. Finally, the ERG had concerns on
the generalizability of the evidence to the UK patient
population.
The Appraisal Committee (AC) considered that
paclitaxel is the most appropriate comparator for the
combination therapy, as its comparative
effectiveness is based on direct evidence. The AC
also considered some of the inputs should be
adjusted for the UK population.
In the end, it was concluded that ramucirumab alone
or with paclitaxel could not be considered a cost-
effective use of National Health Service resources.
In this appraisal, all incremental cost-effectiveness
ratios (ICERs) from the company submission (base-
case, sensitivity/scenario analyses) were far above
the currently accepted threshold. For these cases, a
faster procedure appraisal might be more efficient.
1 Introduction
The National Institute for Health and Care Excellence
(NICE) is an independent organization providing national
guidance on promoting good health and preventing and
treating ill health [1]. The single technology appraisal
(STA) process is designed to provide recommendations on
a single product, device or other technology with a single
indication. The process covers new technologies and
enables NICE to produce guidance shortly after the tech-
nology is introduced into the UK. The NICE Appraisal
Committee (AC) obtains relevant evidence from several
sources: the company submission (CS), a report from the
appointed independent Evidence Review Group (ERG) and
advice from consultees (i.e. patients, experts and other
stakeholders). The CS includes a written report and a
mathematical model that describes the clinical and cost
effectiveness of the technology under investigation. The
ERG, an external organization independent of the NICE,
reviews the CS and produces a summary report and pro-
vides a critique of the submitted evidence. After consid-
eration of all the relevant evidence, the AC formulates
preliminary guidance in the form of the Appraisal Con-
sultation Document (ACD) as to whether or not to rec-
ommend the intervention. The stakeholders are invited to
comment on this ACD and the submitted evidence. A
subsequent ACD may be produced or a Final Appraisal
Determination (FAD) is issued. Once published, NICE
technology guidance provides a legal obligation for NHS
providers to reimburse technologies that have been
approved. This paper presents a summary of the ERG
report and the development of NICE guidance based on the
findings of the AC for the STA of ramucirumab (alone or in
combination with paclitaxel), for treating advanced gastric
cancer or gastro-oesophageal junction (GC/GOJ) adeno-
carcinoma previously treated with chemotherapy. Full
details of all the relevant appraisal documents can be found
on the NICE website [2].
2 The Decision Problem
The indication GC/GOJ refers to cancers that originate in
the lining of the stomach and the gastro-oesophageal
junction. GC/GOJs are rare (designated orphan status by
the European Medicines Agency [EMA]) and aggressive
cancers. The annual incidence of GC/GOJ is low in the
UK; in 2012, there were 5637 new cases of GC and 3085
new cases of GOJ [3]. Of patients diagnosed with GC,
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approximately 80% are diagnosed with advanced, meta-
static disease [4]. The prognosis in this group is very poor
with a 5-year survival rate of approximately 5% [5].
For inoperable patients with advanced GC/GOJ,
chemotherapy is administered. The standard first-line treat-
ment in the UK is a regimen comprising a fluoropyrimidine
and a platinum agent, with or without an anthracycline [6].
For GC/GOJ, there are two NICE guidance documents
available, capecitabine in combination with a platinum-based
regimen [7], and trastuzumab in combination with fluoropy-
rimidine [8], both recommended for first-line treatment.
There is currently no established second-line treatment
and as a consequence, second-line treatments for GC/GOJ
patients vary [6]. Docetaxel, paclitaxel (PAC) and
irinotecan are among the therapies that are administered.
Ramucirumab is a human receptor-targeted monoclonal
antibody that specifically binds to the vascular endothelial
growth factor receptor. It is approved and has been desig-
nated orphan status by the EMA [10, 11] for the treatment
of adult patients with advanced GC/GOJ with disease
progression after prior platinum or fluoropyrimidine
chemotherapy:
• in combination with paclitaxel (RAM ? PAC);
• as monotherapy (RAM), in patients for whom treatment
in combination with PAC is not appropriate.
The remit of this appraisal was specified by NICE’s final
scope [2], which was to assess the clinical and cost effec-
tiveness of ramucirumab within its licensed indication. In
line with its license, the scope addressed the use of
RAM ? PAC as well as RAM; the latter option being for
patients in which treatment in combination with PAC is
inappropriate. The comparators listed in the scope were
docetaxel monotherapy, irinotecan monotherapy, irinote-
can- and fluorouracil-based therapy (FOLFIRI), PAC
monotherapy and best supportive care (BSC).
3 The Independent Evidence Review Group
(ERG) Report
Kleijnen Systematic Reviews Ltd (KSR), in collaboration
with Erasmus University Rotterdam, acted as the ERG, and
reviewed the evidence on the clinical and cost effectiveness
of RAM ? PAC and RAM among adults with advanced
GC/GOJ, who were previously treated with chemotherapy
as submitted by the company (Eli Lilly and Company).
The review embodied three aims:
• to assess whether the CS conformed to the method-
ological guidelines issued by NICE [1];
• to assess whether the company’s interpretation and
analysis of the evidence were appropriate;
• to indicate the presence of other sources of evidence or
alternative interpretations of the evidence that could
inform NICE guidance.
The ERG critically reviewed the evidence in the CS, in
the response to clarification questions and evidence pro-
vided after the publication of the ACD. Furthermore, it
conducted additional literature searches, explored the
impact of assumptions on the incremental cost-effective-
ness ratio (ICER), revised the economic model and
explored additional scenario analyses.
3.1 Summary of the Clinical Evidence
The CS included a systematic review of the literature on
the clinical/cost effectiveness of ramucirumab.
3.1.1 Ramucirumab Monotherapy
Estimation of the efficacy of RAM compared with BSC
relied on the REGARD trial (Ramucirumab monotherapy
for previously treated advanced gastric or gastro-oe-
sophageal junction adenocarcinoma) [9]. In this global,
multicentre trial, adult patients with advanced GC/GOJ,
who progressed after chemotherapy (n = 355), were ran-
domized (2:1) to receive BSC and either ramucirumab
(8 mg/kg administered intravenously [IV] every 2 weeks)
or placebo.
Randomization was stratified by weight loss, geographic
location and location of the primary tumour. Overall sur-
vival (OS) was the primary outcome. Key secondary out-
comes included progression-free survival (PFS), overall
response rate (ORR) and quality of life (QoL). All analyses
were performed using the intention-to-treat (ITT) popula-
tion. The OS and PFS results are given in Table 1.
Health-related QoL in REGARD was assessed using the
European Organisation for Research and Treatment of
Cancer (EORTC) QLQ-C30 instrument [10]. At 6 weeks,
the proportion of patients with improved or stable QoL was
higher for the ramucirumab arm (34.1%) than for the pla-
cebo arm (13.7%); but the difference between these two
arms was not statistically significant (p = 0.23).
Overall safety results from REGARD showed that 45%
of the patients in the ramucirumab arm had at least one
serious adverse event (AE), compared with 44% of the
patients in the placebo arm. The proportion of patients who
stopped treatment was 10.5% in the ramucirumab arm and
6% in the placebo arm.
3.1.2 Ramucirumab plus Paclitaxel
Estimation of the efficacy of RAM ? PAC compared with
PAC relied on one global, multi-centre trial (RAINBOW;
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Ramucirumab plus paclitaxel versus placebo plus pacli-
taxel in patients with previously treated advanced gastric or
gastro-oesophageal junction adenocarcinoma) [11], in
which patients with advanced GC/GOJ who had disease
progression after chemotherapy (n = 665) were random-
ized (1:1) to receive RAM 8 mg/kg plus PAC 80 mg/kg, or
placebo plus PAC 80 mg/kg administered IV. RAM was
given every 2 weeks whereas PAC was given on Days 1, 8
and 15 of each 28-day cycle.
Randomization was stratified by geographic location,
time to progression from the start of first-line chemother-
apy (\6 months or not) and disease measurability (mea-
surable or not). The primary outcome was OS, key
secondary outcomes included PFS, ORR and QoL. All
analyses were performed on the ITT population. The OS
and PFS results are given in Table 2.
Health-related QoL in RAINBOW was also assessed
using the EORTC QLQ-C30 instrument [10]. RAM ? -
PAC was associated with statistically significant improved
outcomes for two symptom scales (i.e. emotional function
and nausea and vomiting), compared with PAC.
A similar percentage of patients in both arms stopped
treatment because of AEs (11.8% in the RAM ? PAC arm
and 11.3% in the PAC arm). The most frequently reported
treatment-emergent serious AE was neutropenia, 54.4% in
the RAM ? PAC arm and 31.0% in the PAC arm.
3.1.3 Network Meta-Analysis (NMA)
The company carried out a NMA to compare the OS of
RAM ? PAC with BSC and docetaxel. The company
identified 23 trials for inclusion in the systematic review;
however, only the five trials listed in Table 3 were included
in the NMA of OS. The other 18 trials (out of the identified
23) were not included as they were considered to compare
treatments that were not in the scope [2]. However, among
these excluded studies, Sym et al. [12] compared irinotecan
with FOLFIRI, both of which were listed as comparators in
the scope. Upon request from the ERG, in the company’s
response to clarification letter, FOLFIRI was incorporated
into the evidence network using Sym et al. [12].
The hazard ratio (HR) results from the OS NMA are
given in Table 4.
In order to compare the PFS of RAM ? PAC with BSC
and docetaxel, additional assumptions were needed since
some studies did not report PFS HRs [13, 14, 16]. Using
the PFS HRs reported [9, 11, 15] and assuming HR = 1
(standard error [SE] = 0.01) between RAM, irinotecan and
docetaxel, the results from the NMA suggested that
RAM ? PAC was associated with a statistically signifi-
cantly improved PFS compared with BSC (HR 0.27; 95%
CI 0.14–0.53) and docetaxel (HR 0.56; 95% CI 0.41–0.76).
Table 1 OS and PFS results
from the REGARD study
Median OS RAM (months) Median OS BSC (months) HR (RAM vs BSC)
5.2 (95% CI 4.4–5.7) 3.8 (95% CI 2.8–4.7) 0.776 (95% CI 0.603–0.998)
Median PFS RAM (months) Median PFS BSC (months) HR (RAM vs BSC)
2.1 (95% CI 1.5–2.7) 1.3 (95% CI 1.3–1.4) 0.483 (95% CI 0.376–0.620)
BSC Best supportive care, HR hazard ratio, OS overall survival, PFS progression-free survival, RAM
ramucirumab monotherapy
Table 2 OS and PFS results
from the RAINBOW study
Median OS RAM ? PAC (months) Median OS PAC (months) HR (RAM ? PAC vs PAC)
9.63 (95% CI 8.6–10.8) 7.36 (95% CI 6.3–8.4) 0.807 (95% CI 0.678–0.962)
Median PFS RAM ? PAC (months) Median PFS PAC (months) HR (RAM ? PAC vs PAC)
4.4 (95% CI 4.2–5.3) 2.9 (95% CI 2.8–3.0) 0.635 (95% CI 0.536–0.752)
HR Hazard ratio, OS overall survival, PAC paclitaxel monotherapy, PFS progression-free survival,
RAM ? PAC ramucirumab combination therapy
Table 3 Trials that were included in the network meta-analysis
Trial Treatment arms
RAINBOW [11] RAM ? PAC vs PAC
COUGAR-02 [13] Docetaxel vs BSC
Roy et al. [14]a Docetaxel vs irinotecan
Hironaka et al. [15] PAC vs irinotecan
Thuss-Patience et al. [16] Irinotecan vs BSC
Sym et al. [12] Irinotecan vs FOLFIRI
BSC Best supportive care, FOLFIRI fluorouracil-based therapy, PAC
paclitaxel monotherapy, RAM ? PAC ramucirumab combination
therapy
a Roy et al. [14] was included only in one of the sensitivity analyses,
as it was not a phase III trial
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3.2 Critique of the Clinical Evidence
3.2.1 Ramucirumab Monotherapy
REGARD was deemed to be a good-quality randomized
controlled trial. The uncertainty about long-term efficacy
was considered to be small, because both OS and PFS data
were mature.
In the final scope, RAM monotherapy was indicated for
patients who were not suitable for PAC. However, in
REGARD’s eligibility criteria, nothing was mentioned on
patients’ suitability for PAC treatment. Therefore, the
clinical evidence for ramucirumab monotherapy was not
necessarily based on the indicated population (patients not
suitable for PAC).
Furthermore, in the submission, the company assumed
that if a patient is not suitable for PAC, s/he is not suit-
able for any other cytotoxic chemotherapy either. If this is
plausible, the comparison of RAM versus BSC is in line
with the NICE final scope. Otherwise, comparisons with
cytotoxic chemotherapy other than PAC (i.e. docetaxel,
irinotecan and FOLFIRI) should have been included.
An indirect comparison with docetaxel, using the
COUGAR-02 [13] trial (Docetaxel versus active symptom
control for refractory oesophagogastric adenocarcinoma),
showed that the hazard ratio of OS of monotherapy
ramucirumab versus docetaxel was not significantly dif-
ferent from 1 (HR 1.16; 95% CI 0.77–1.73).
3.2.2 Ramucirumab Combination Therapy
RAINBOW was deemed to be a good-quality randomized
controlled trial. Uncertainty about long-term efficacy was
considered to be small, because both OS and PFS data were
mature. There were few (n = 15) UK patients in the trial,
in the region 1 stratum (includes patients from Europe,
Israel, USA and Australia).
The ERG concluded that the NMA results should be
interpreted with caution, due to considerable heterogeneity
resulting from the inclusion of predominantly Asian studies
(e.g. the Hironaka et al. [15] study was based only on
Japanese patients). There are substantial differences
between Asian and Western countries in terms of gastric
cancer incidence, histology, screening and treatment
approaches [17–19].
Furthermore, the study by Thuss-Patience et al. [16],
which was included in the NMA, was underpowered
(N = 40) since it was closed prematurely because of poor
recruitment. The ERG also stated that the NMA would
have been more reliable if the results from Roy et al. [14],
which also included an irinotecan arm, were included in the
base case.
3.3 Summary of the Cost-Effectiveness Evidence
The company submitted two separate partitioned survival
models to assess the cost effectiveness of RAM and
RAM ? PAC. The structures of both models were the
same, comprising three states: pre-progression, post-pro-
gression and death. Patients entered the model in the pre-
progression state. The cycle length was 1 week, and half-
cycle correction was applied. Lifetime horizon was used in
both models. Both models adopted a National Health
Service (NHS) perspective and costs and benefits were
discounted at a rate of 3.5%.
The only comparator in the monotherapy economic
model was BSC since the company claimed that people
who are ineligible for PAC are not eligible for any cyto-
toxic chemotherapy.
The comparators in the combination therapy model were
BSC and docetaxel. According to the company, a com-
parator was eligible for inclusion if it was used sufficiently
(i.e. above an arbitrary threshold of 10% use). PAC was
only included as a means of validating the model results by
comparing model outcomes with the clinical evidence from
RAINBOW.
Transition probabilities between the health states for
either RAM or RAM ? PAC were determined from para-
metric survival functions fitted to the OS and PFS data
from the RAINBOW and REGARD trials. Transition
probabilities for the comparators docetaxel and BSC were
estimated using HRs from the NMA.
In the monotherapy model, the company used the
gamma distribution to model OS and the interval-censored
log-normal distribution to model PFS.
For the combination therapy model, the company used
the OS Kaplan–Meier curve from RAINBOW until the end
of the follow-up period and afterwards an exponential
extrapolation was assumed. An interval censored Weibull
distribution was chosen for PFS.
Table 4 Hazard ratio results from the overall survival network meta-analysis
Hazard ratio (95% CI)
BSC Docetaxel PAC Irinotecan FOLFIRI
RAM ? PAC 0.34 (0.17–0.71) 0.51 (0.23–1.13) 0.81 (0.68–0.96) 0.71 (0.52–0.99) 0.86 (0.45–1.65)
BSC Best supportive care, FOLFIRI fluorouracil-based therapy, PAC paclitaxel monotherapy, RAM ? PAC ramucirumab combination therapy
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Utility values for the pre-progression and the post-pro-
gression health states were derived from EQ-5D data from
RAINBOW in both models. For the pre-progression state,
the average utility of the patients at baseline was used,
whereas for the post-progression state, the average utility
of the patients who discontinued treatment due to pro-
gressive disease was utilized. According to the company,
data from the monotherapy trial (REGARD) could not be
used since only EORTC-QLQ-C-30 data were collected
and post-baseline data was insufficient due to rapid disease
progression in both arms.
Utility decrements were applied for AEs in both models.
AEs were included based on grade (i.e. 3 and 4) and
occurrence (i.e.[5% in any of the relevant trials). Utility
decrements were taken from the literature in other cancer
areas [20–23]. Duration of AEs was taken from the NICE
STA for pixantrone in non-Hodgkin’s B cell lymphoma
[24].
A utility increment was applied in the combination
therapy model to the responders. For RAM ? PAC, the
ORR was taken from RAINBOW (27.9%). The company
assumed the ORR for docetaxel was similar to PAC in
RAINBOW (16.1%). Since ORR for BSC and RAM in
REGARD was very low (2.6 and 3.4%), no response was
assumed for BSC and RAM in the monotherapy model.
The costs included in the model were for drug acquisi-
tion, drug administration, monitoring/testing and follow-up
care. All costs used in the model calculations were based
on their 2014 values. The prices of generic chemotherapies
were taken from the electronic market information tool
(eMIT) [25]. Non-generic drug prices were taken from the
British National Formulary (BNF) [26]. The drug dosages,
treatment durations and relative dose intensity data for
RAM, RAM ? PAC and docetaxel were derived from
REGARD, RAINBOW and COUGAR-02 [27]. In the base
case, drug wastage from open vials was assumed and pre-
medication for RAM ? PAC and DOC treatments were
based on their summary of product characteristics. The cost
components of BSC were identified from a review of
hospital medical records [6]. Drug administration costs
were based on NHS reference costs.
Costs for tests and monitoring were based on expert
opinion. Costs of grade 3 or 4 AEs were based on NHS
reference costs. Hospitalization costs were based on trial
data. It was assumed that only 12% of patients receive a
third-line therapy and relevant costs (drug acquisition,
administration and follow-up care) were applied in the first
cycle after progression. Inflation-adjusted terminal care
costs from Coyle et al. [23] were applied in the base case.
The base-case deterministic ICER for RAM versus BSC
was £188,640 per QALY gained. Deterministic sensitivity
analysis showed that the ICER was most sensitive to hos-
pital admission rates, length of hospital stay, assumptions
on vial waste and extrapolation of post-progression sur-
vival. Assuming a log-normal distribution (the distribution
with a better fit using the goodness-of-fit diagnostic tests)
instead of gamma distribution for OS reduced the ICER to
£174,485 per QALY gained.
The base-case deterministic ICER for RAM ? PAC
versus BSC was £118,209 per QALY gained. The deter-
ministic sensitivity analysis showed that the ICER was
most sensitive to the assumptions surrounding source of
drug prices (eMIT vs BNF), length of hospital stay, relative
dose intensity and body surface area/weight. Assuming a
Weibull distribution for OS gave similar results to the base-
case analysis (£117,236 per QALY gained), whereas the
log-logistic distribution reduced the ICER to £96,103 per
QALY gained. In a scenario analysis, the OS, PFS and time
on treatment were adjusted based on region 1 specific data,
which led to similar ICER results.
3.4 Critique of the Cost-Effectiveness Evidence
The ERG considered excluding comparators due to an
arbitrary threshold (10%) not appropriate and found that
treatments listed in the scope for the combination therapy
model (PAC, irinotecan and FOLFIRI) should have been
included. Furthermore, even under the 10% threshold rule,
the ERG found that PAC should have been included since
10.5% of second-line GC/GOJ patients received PAC [6].
In general, the process for extrapolating survival curves
was clear, but the choice of the survival regression model
was not always consistent. It was also not clear which
approach was followed for interval-censoring adjustments.
In the model, mortality in the pre-progression state was
neglected while calculating the number of ‘newly pro-
gressed patients’. However, its impact on incremental
results was expected to be low because further-line treat-
ment costs, derived from the number of ‘newly progressed
patients’, constitute a minor part of the total costs.
There were also some issues concerning the generaliz-
ability of results from RAINBOW and REGARD for UK
patients. For instance, the ERG believed that region 1 data
better reflects the UK population weight and body surface
area for calculating the drug costs for RAM ? PAC, as the
whole RAINBOW population included a lot of patients
from Asian countries, who had relatively lower weight and
body surface areas.
Also, double counting of hospitalization costs was
identified because, in addition to the modelled costs based
on observed hospitalization rates, Health Resource Groups’
codes referring to AEs in the model also included hospi-
talizations. In its response to the clarification letter, the
company provided a scenario that reduced the rate of
hospitalizations by an estimate of the proportion of hos-
pitalizations due to AEs. The ERG used these adjusted
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hospitalization rates in its exploratory analyses for its base
case. In addition, the ERG found a few minor programming
errors in the original company model; correcting those had
negligible impact on the ICER.
3.5 Additional Exploratory Analyses Conducted
by the ERG
3.5.1 Additional Comparators
In exploratory analyses, the ERG included the comparators
defined in the final scope for the combination therapy
model. These analyses were presented using the company’s
base-case assumptions (except confirmed programming
errors). The results of these exploratory analyses are pre-
sented in Table 5. They should be interpreted with caution
because they relied on the NMA, which was associated
with significant uncertainty as a result of heterogeneity
between the studies.
3.5.2 ERG Base-Case and Scenario Analyses
The ERG base case included the adjustments listed in
Table 6, and the results are given in Table 7. In addition,
the ERG explored three different scenarios in the combi-
nation therapy model, as listed in Table 8.
3.5.3 End-of-Life Considerations
NICE end-of-life (EOL) supplementary advice at the time
applied in the following circumstances and when all cri-
teria referred to in Table 9 are satisfied.
For RAM ? PAC, the company claimed that EOL cri-
teria should be applied based on the mean additional sur-
vival in comparison with BSC (6.03 months) and docetaxel
(4.13 months). However, the additional survival of
RAM ? PAC versus other comparators in the scope was
1.44 months for PAC, 2.27 months for irinotecan and
1.1 months for FOLFIRI. Therefore, the ERG argued the
EOL criteria were not fulfilled.
3.6 Conclusions of the ERG Report
In REGARD, RAM was associated with a slightly higher
OS and PFS compared with BSC, and RAINBOW showed
more favourable OS and PFS results for RAM ? PAC in
comparison with PAC. The NMA suggested some gains in
OS and PFS for RAM ? PAC compared with BSC, and
gains in PFS for RAM ? PAC in comparison with doc-
etaxel. The ERG considered that the results based on indi-
rect comparisons should be interpreted with caution due to
significant heterogeneity between studies. For instance,
Table 5 Pairwise base-case
results for additional
comparators compared with
ramucirumab plus paclitaxel
using the company’s base-case
assumptionsa
Intervention Comparator Incremental QALY Incremental cost (£) ICER (per QALY gained) (£)
RAM ? PAC BSC 0.33 39,584 118,174
Docetaxel 0.24 34,153 145,302
Irinotecan 0.15 31,238 213,015
PAC 0.1 26,790 273,657
FOLFIRI 0.1 28,166 294,362
BSC Best supportive care, FOLFIRI fluorouracil-based therapy, ICER incremental cost-effectiveness ratio,
PAC paclitaxel monotherapy, QALY quality-adjusted life-year, RAM ? PAC ramucirumab combination
therapy
a Company’s base-case assumptions were used except for a corrected programming error
Table 6 List of adjustments on company submission base case
No. Change on the company base case
1 Removal of programming errors (half cycle correction and
docetaxel price calculations)
2 Weight/body surface area and treatment-specific hospital length
of stay of patients based on region 1, not all patients in the
trials
3 Correction of double counting for hospitalizations due to
adverse events
Table 7 The results of the ERG and CS base-case ICERs (Cost per
QALY gained)
ERG base-case
ICER (per QALY
gained) (£)
CS base-case
ICER (per QALY
gained) (£)
Monotherapy model
RAM vs BSC 188,055 188,640
Combination therapy model
RAM ? PAC vs BSC 129,431 118,209
RAM ? PAC vs docetaxel 168,164 148,769
RAM ? PAC vs PAC 359,794 NA
BSC Best supportive care, CS Company submission, ERG evidence
review group, FOLFIRI fluorouracil-based therapy, ICER incremental
cost-effectiveness ratio, NA not available, PAC paclitaxel monother-
apy, QALY quality-adjusted life-year, RAM ramucirumab monother-
apy, RAM ? PAC ramucirumab combination therapy
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some studies were predominantly Asian, and the histology
and treatment pattern of gastric cancer between Western
patients and Asian patients might be very different [17–19].
By correcting issues in the model and changing a few
input parameters, a new ERG base case was defined for
both monotherapy and combination therapy models. The
ERG conducted some exploratory analyses in which
additional comparators from the NICE scope were inclu-
ded. Furthermore, additional scenario analyses were con-
ducted in the combination therapy model. In all analyses,
the ICER of RAM ? PAC or RAM compared with any one
of the comparators was never below £90,000 per QALY
gained. Similarly, the probability of RAM ? PAC or RAM
becoming the most cost-effective therapy was negligible
for thresholds below £100,000 per QALY gained in all
analyses.
In order to improve the robustness of the health eco-
nomic results for the UK, a direct comparison of RAM and
RAM ? PAC with all of the relevant comparators among a
predominantly western patient population would be nec-
essary. In addition, QoL data for RAM monotherapy and
for comparators among the targeted population (i.e.
patients ineligible for PAC combination therapy) would
reduce the uncertainty around utilities.
Nevertheless, regardless of any problems with the evi-
dence and the model, the ICERs from even the company
base case far exceeded the usual threshold of £20,000 to
£30,000 per QALY gained and even the EOL threshold of
£50,000 per QALY gained.
3.6.1 Key Methodological Issues
For many of the key cost-related inputs (i.e. body weight,
hospitalization rate, length of stay, etc.), data from all
patients in the REGARD and RAINBOW trials were used,
but average estimates from these trials may not be gener-
alizable to the UK population as the body weight/surface as
well as the gastric cancer histology and treatment patterns
in the Asian population might differ from those in the
Western population [17–19].
If direct comparisons based on phase III randomized
controlled trials for all relevant comparators from the scope
are not available, STAs often rely on indirect treatment
comparisons. As was the case in this STA, sometimes these
analyses involve assumptions that are not evidence based
(e.g. assuming PFS HR = 1 for RAM vs docetaxel). Also,
this STA revealed that decisions regarding exclusion of
trials, (e.g. Roy et al. [14]) might influence outcomes
substantially. Finally, results of indirect treatment com-
parisons should be interpreted with extreme caution if these
are obtained by pooling data from heterogeneous trials.
4 National Institute for Health and Care
Excellence Guidance
4.1 Preliminary Guidance
The Committee considered the company’s decision prob-
lem, and noted that it was in line with the NICE scope, with
the exception of the choice of comparators.
While BSC would be the only comparator for RAM, the
Committee concluded that for people for whom
Table 8 Description and impact of the ERG scenarios
Description of the ERG scenario Impact of the scenario
Including the results from Roy et al. [14] to the OS NMA Increase in ICER around £14,000 per QALY gained for RAM ? PAC
vs BSC compared with the ERG base case
Using direct evidence from the RAINBOW trial and not NMA for the
efficacy data
ICER for RAM ? PAC compared with PAC increased from the ERG
base case of £359,794 per QALY gained to £392,108 per QALY
gained
Implementation of time-varying utility values that are directly derived
from the RAINBOW trial in the model, instead of a single, uniform
utility value for the pre-progression state in all cycles
This resulted in an ICER of £408,223 per QALY gained for
RAM ? PAC vs PAC
BSC Best supportive care, ERG evidence review group, ICER incremental cost-effectiveness ratio, NMA network meta-analysis, OS overall
survival, PAC paclitaxel monotherapy, QALY quality-adjusted life-year, RAM ramucirumab monotherapy, RAM ? PAC ramucirumab combi-
nation therapy
Table 9 The end-of-life criteria for the National Institute for Health
and Care Excellence (NICE)
Short life expectancy, normally\24 months on current National
Health Service (NHS) treatment
The intervention offers an extension to life, normally of at least an
additional 3 months, compared with current NHS treatment
The treatment is licensed or otherwise indicated for small patient
populations (this criterion has subsequently been removed) [28]
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RAM ? PAC is appropriate, PAC and docetaxel are both
relevant comparators.
The Committee concluded that the REGARD and
RAINBOW trials formed suitable evidence on which it
could base its decision on the clinical efficacy of RAM and
RAM ? PAC.
For combination therapy, the Committee considered that
there was no reason to use the NMA results, rather than
using relevant head-to-head data from a good-quality,
international, randomized controlled trial (RAINBOW)
with mature OS and PFS data.
For cost effectiveness, the Committee agreed with the
error corrections and adjustments carried out by the ERG to
use region 1 data for body surface area and body weight, to
correct for double counting of hospitalizations, and to
adjust length of hospitalization stay for region 1. It con-
cluded that the model submitted by the company was
robust and suitable for the purposes of its decision making
and that the ERG’s suggested amendments to the model
were appropriate.
The Committee considered the most robust analysis was
the ERG’s exploratory analysis, which used RAINBOW
trial data for RAM ? PAC compared with PAC, and used
time-varying utility values from RAINBOW, collected
during the pre-progression period. This analysis provided
the most plausible ICER of RAM ? PAC versus PAC for
people with GC/GOJ for whom treatment in combination
with cytotoxic chemotherapy is appropriate: £408,200 per
QALY gained (with incremental costs of £35,100 and
incremental QALYs of 0.09).
The Committee concluded that the most plausible ICER
for people with GC/GOJ adenocarcinoma for whom further
cytotoxic chemotherapy is not appropriate (i.e. RAM vs
BSC) was £188,100 per QALY gained (representing
incremental costs of £22,500 and incremental QALYs of
0.12).
According to the Committee, EOL criteria were not met,
and the overall conclusion was that, for the treatment of
adults with advanced GC/GOJ adenocarcinoma with dis-
ease progression after platinum and fluoropyrimidine
chemotherapy, neither RAM ? PAC nor RAM (where
paclitaxel is not appropriate) were a cost-effective use of
NHS resources at the usual range of ICERs (£20,000–
£30,000 per QALY gained).
4.2 Response to the Preliminary Guidance
The response of the company to the ACD first focused on
the unwarranted variation and inequity in the provision of
second-line GC/GOJ treatments in clinical practice, which
might be aggravated by the lack of a licensed second-line
treatment. Secondly, the company expressed that the
weaknesses of the NMA were overestimated (arguing that
the Thuss-Patience et al. study [16] should be considered as
systematically unbiased, and that the Hironaka et al. study
[15] results are transferable to the UK), and that the NMA
results should be considered sufficiently plausible to permit
its use. Thirdly, concerning the comparators, the company
did not agree with the Committee’s decision that the
comparison of PAC with RAM ? PAC based on RAIN-
BOW data provided a good basis for assessing the EOL
criteria and the most plausible ICER estimates, because the
company considered BSC and docetaxel were more rele-
vant and commonly used comparators. Finally, the com-
pany discussed a number of potential factual inaccuracies
and inconsistencies, which were clarified before the final
guidance.
4.3 Final Guidance
The Committee considered the comments raised by the
company in its response to the ACD. However, this did not
lead to any change in the ACD and the Committee con-
cluded that RAM or RAM ? PAC could not be recom-
mended within the market authorization.
5 Conclusions
This appraisal demonstrated that the selection of the rele-
vant comparators is crucial and might have a substantial
impact on the ICER. Even though the comparators were
identified in the scope, the company and the decision
maker had different views on the relevance of some of the
comparators for the inclusion in the cost-effectiveness
analysis.
Similarly, the inclusion of available evidence for the
NMA is another crucial decision that may have a consid-
erable impact on ICER, and different parties may have
differing views on this decision as well.
Another important issue is the generalizability of the
evidence to the UK patient population. This STA showed
that when differences are expected between the UK pop-
ulation and the population on which the evidence is built
(e.g. weight/body surface area, histology and treatment
patterns of the Asian patients), it might be important to
adapt these analyses for the UK.
Finally, this appraisal shows that decision makers may
prefer to base their decision on direct evidence rather than
indirect evidence, especially if the latter has the potential to
be heterogeneous and biased.
Despite these differing opinions between the company and
decision maker, in all of the analyses from the company and
the ERG, ICERs of monotherapy and combination therapy
were always far above the currently accepted thresholds. This
review described a STA process without a patient access
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scheme (PAS), with unacceptably high ICERs, even in the
best-case scenarios of the company. In the case of no PAS, if
the best-case scenario from the company is not within the
reach of an acceptable cost-effectiveness ratio, one may
wonder to what extent the current STA process, in its full
scale, is a cost-effective way of spending NHS resources.
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